New advances in biology and treatment of gastrointestinal stromal tumours (GISTs).
Gastrointestinal stromal tumours (GISTs) are a precise oncogenetic entity that has started the new era of targeted therapies in solid tumours. GISTs are now a model to understand the role of oncogenic kinase mutation in tumourigenesis, duplication, cell regulation, apoptosis and drug resistance. Ninety-five percent of GISTs have some activacting mutation of c-KIT or PDGFRA tyrosine kinase. The studies of the last two years have found concrete correlations between mutations and anatomical locations of GISTs, prognosis, response to therapy and resistance to therapy. Genotyping has increased of importance in the last years as a new field for translational researches. The important advances made in molecular studies are now a practical tool in diagnosis and therapy of GISTs.
Comandone
A
A
Department of Oncology, Gradenigo Hospital and Gruppo Piemontese Sarcomi, Turin, Italy. alessandro.comandone@h-gradenigo.it
Boglione
A
A
Bergnolo
P
P
Berno
E
E
D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D009154:Mutation